A panelist discusses how digital patient engagement tools and collaboration with advocacy groups can enhance treatment adherence and care coordination while providing vital support and resources for individuals managing Lambert-Eaton myasthenic syndrome (LEMS).
Video content above is prompted by the following:
Depemokimab Reduces Exacerbations Regardless of Baseline Asthma Control
July 3rd 2025Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.
Read More